229. Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details

Clinical trials : 44 / Drugs : 22 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 14

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01842386 (ClinicalTrials.gov)	April 29, 2014	25/4/2013	Rituximab for Anti-cytokine Autoantibody-Associated Diseases	Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases	Pulmonary Alveolar Proteinosis (PAP);Severe Mucocutaneous Candidiasis	Drug: Rituximab	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	N/A	All	7	Phase 1	United States
2	NCT00552461 (ClinicalTrials.gov)	January 2007	31/10/2007	Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis	Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis	Pulmonary Alveolar Proteinosis;Primary Disease	Drug: rituximab	East Carolina University	Genentech, Inc.	Recruiting	18 Years	N/A	Both	10	Phase 2	United States